Amgen will expand its US drug substance manufacturing capabilities with a new USD $1bn facility in North Carolina.
This is the second site of its kind in the area, and will allow Amgen to better serve its US pharmaceutical clients.
The expansion will also enhance the company's biomanufacturing network, allowing it to deliver therapeutics to patients across the globe.
Through this investment, Amgen will have put more than $1.5bn into Holly Springs — which builds on the $550m commitment the company made into building a biologics manufacturing facility.
While creating 370 new jobs for local individuals, Amgen's novel facility will also be designed with sustainability in mind.
Amgen chose North Carolina as it is a notable hub for life science companies, with a high proportion of skilled workers living in this area.
CEO and Chair of Amgen, Robert A Bradway, commented: "North Carolina will be an important part of our global manufacturing network as we continue to grow. By expanding into our region, we can successfully bring transformative medicines to patients around the world."
"North Carolina's reputation as one of the world's leading centers for biotechnology soars even higher with today's decision by Amgen," said North Carolina Governor Roy Cooper.
"North Carolina offers everything an innovative biotech company needs to succeed, especially our highly trained, dedicated and diverse workforce which is fine-tuned to the needs of this critical industry."